skylimit hat am 20.08.2012 - 19:09 folgendes geschrieben:
QuoteDisplay MoreFlacrash hat am 20.08.2012 - 18:44 folgendes geschrieben:
Offiziell wurde sie kurz vor 17 Uhr publiziert. Hätte also locker Einfluss auf den Kurs haben können/müssen:
DJ newsbox.ch/ Newron raises CHF4.7m through a Private Placement
20.08.12 15:57:10- DJPN
CodeDisplay MoreNewron raises CHF4.7m through a Private Placement Milan, Italy - 20 August, 2012 - Newron Pharmaceuticals S.p.A. ("Newron", SIX: NWRN), a research and development company focused on Central Nervous System (CNS) and pain therapies, today announced that it has successfully raised funds of approximately CHF4.7m (EUR3.9m) through a private placement. In total, 798,945 immediately tradeable shares were placed with new and existing institutional investors. Stefan Weber, Newron's CEO, said: "We are delighted to have the support of a strong group of international institutional investors. This is an exciting time for Newron as we look forward to regulatory submission for safinamide and focus on the next priorities in our innovative CNS pipeline." About Newron Pharmaceuticals Newron (SIX: NWRN) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Phase III trials of safinamide for the treatment of Parkinson's disease (PD) have recently been completed. Based on the phase III results of safinamide, Newron is working to expedite the global filing of the compound, together with its partners. Zambon Group has the rights to commercialise safinamide globally, excluding Japan and other key Asian territories, and Meiji Seika has the rights to develop and commercialise safinamide in Japan and other key Asian territories. Newron's additional projects are at various stages of preclinical and clinical development, including HF0220 for neuroprotection, ralfinamide for pain, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases. www.newron.com For more information, contact: +--------------+-------------+ |Media |Investors and| | |analysts | +--------------+-------------+ |Italy | | | | | |Stefan Weber -|Stefan Weber | |CEO |- CEO | | | | |Phone: +39 02 |Phone: +39 02| |6103 46 26 |6103 46 30 | | | | |E-mail: |E-mail: | |pr@newron.com |ir@newron.com| | | | | | | | | | |UK/Global | | |media | | | | | |Julia Phillips| | | | | |FTI Consulting| | | | | |Phone: +44 (0)| | |20 7269 7187 | | | | | | | | | | | |Switzerland | | | | | |Martin | | |Meier-Pfister | | | | | |IRF | | |Communications| | | | | |Phone: +41 43 | | |244 81 40 | | | | | | | | +--------------+-------------+ | | | +--------------+-------------+ Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron's ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron's anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Media Release (PDF) +-------------++--------------++----------------+ |Provider ||Channel ||Contact | +-------------++--------------++----------------+ |Tensid Ltd., ||newsbox.ch ||Provider/Channel| |Switzerland ||www.newsbox.ch||related | |www.tensid.ch|| ||enquiries | | || ||marco@tensid.ch | | || ||+41 41 763 00 50| +-------------++--------------++----------------+ | || || | +-------------++--------------++----------------+ (END) Dow Jones Newswires 20-08-12Code1457GMT
Auf der NEWRON HP erschien die Meldung erst nach Börsenschluss und nicht so wie bei der newsbox.ch
